Please login to the form below

Not currently logged in

EMA picks projects for adaptive licensing project

European Medicines Agency (EMA)Begins discussions on how the model will be implemented in practice

Astellas forges $675m muscle alliance with Cytokinetics

Extends collaboration to include neuromuscular diseases

NICE rejection of three ovarian cancer drugs stands

Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease

BioCryst gets FDA nod for first intravenous flu drug

US regulator Food and Drug Administrator FDAExpects to launch Rapivab in time for this year's flu season

EU approval for Lilly's Cyramza in stomach cancer

lilly cyramza ramucirumabFollows shortly after the drug's US approval in non-small cell lung cancer

Sovaldi dropped by Express Scripts in favour of Viekira Pak

gilead-sciences-sovaldiPharmacy benefits organisation ramps up US pricing pressure on Gilead

BMS cancer drug Opdivo gains US melanoma licence

Bristol-Myers Squibb (BMS) buildingTherapeutic vaccine can now be used against the deadliest form of skin cancer

FDA backs Cubist's antibiotic Zerbaxa

Cubist pharmaCombination cephalosporin and beta lactamase inhibitor wins US approval

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Clark Health Communications

Clark Health Communications is a fresh thinking health and medical communications agency. Our team is made up of experienced and...

Latest intelligence

Can Cinderella save us?
The impending threat of antibiotic resistance
Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do?...
UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...